ADC Therapeutics SA (ADCT)

NYSE: ADCT · IEX Real-Time Price · USD
1.03
-0.08 (-7.21%)
Dec 5, 2023, 4:00 PM EST - Market closed
-7.21%
Market Cap 89.51M
Revenue (ttm) 122.57M
Net Income (ttm) -178.51M
Shares Out 80.64M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 411,587
Open 1.09
Previous Close 1.11
Day's Range 0.97 - 1.09
52-Week Range 0.36 - 5.75
Beta 1.24
Analysts Hold
Price Target 4.20 (+307.77%)
Earnings Date Nov 7, 2023

About ADCT

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a mon... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 15, 2020
Employees 317
Stock Exchange NYSE
Ticker Symbol ADCT
Full Company Profile

Financial Performance

In 2022, ADCT's revenue was $209.91 million, an increase of 518.89% compared to the previous year's $33.92 million. Losses were -$155.80 million, -32.27% less than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ADCT stock is "Hold." The 12-month stock price forecast is $4.2, which is an increase of 307.77% from the latest price.

Price Target
$4.2
(307.77% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads bas...

20 days ago - GlobeNewsWire

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that th...

4 weeks ago - GlobeNewsWire

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

3Q 2023 ZYNLONTA® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions

4 weeks ago - GlobeNewsWire

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferi...

4 weeks ago - GlobeNewsWire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination

4 weeks ago - GlobeNewsWire

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m....

6 weeks ago - GlobeNewsWire

Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibo...

2 months ago - GlobeNewsWire

ADC Therapeutics to Participate in September Investor Conferences

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in S...

3 months ago - GlobeNewsWire

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals

3 months ago - GlobeNewsWire

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

2Q 2023 ZYNLONTA® 1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth

4 months ago - GlobeNewsWire

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. E...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contac...

4 months ago - PRNewsWire

Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: AD...

4 months ago - GlobeNewsWire

ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy

ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concern...

5 months ago - Reuters

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (Cli...

5 months ago - GlobeNewsWire

ADC Therapeutics Announces Evolution of Board of Directors

Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, Ju...

6 months ago - GlobeNewsWire

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in...

6 months ago - GlobeNewsWire

ADC Therapeutics to Participate in the Jefferies Healthcare Conference

LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferi...

6 months ago - GlobeNewsWire

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in ...

7 months ago - Business Wire

ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Glob...

7 months ago - Business Wire

ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy. “2023 is a pivotal year...

7 months ago - Business Wire

ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financi...

7 months ago - Business Wire

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securi...

9 months ago - Business Wire

ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43rd Annual Health Car...

9 months ago - Business Wire

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates. “...

10 months ago - Business Wire